Commission Delegated Regulation (EU) 2024/197of 19 October 2023amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances(Text with EEA relevance)

Commission Delegated Regulation (EU) 2024/197 of 19 October 2023 amending Regulation (EC) No 1272/2008 as regards the harmonised classification and labelling of certain substances (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 OJ L 353, 31.12.2008, p. 1. , and in particular Article 37(5) thereof, Whereas: (1) Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation. (2) Proposals to introduce harmonised classification and labelling of certain substances and to update the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (the Agency) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted, after having taken account of the comments received from the parties concerned, the following opinions The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/.The opinion of 16 September 2021 concerning a reassessment at the request of the Commission is accessible via the following website: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests. on those proposals: Opinion of 18 March 2021 concerning benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate; Opinion of 18 March 2021 concerning benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1); Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1); Opinion of 18 March 2021 concerning reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1); Opinion of 18 March 2021 concerning 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF;

Opinion of 18 March 2021 concerning cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal [1], (2E)-3-phenylprop-2-enal [2]; Opinion of 18 March 2021 concerning benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine; Opinion 18 March 2021 concerning 3,3'-dimethylbiphenyl-4,4'-diyl diisocyanate; Opinion of 18 March 2021 concerning foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea; Opinion of 18 March 2021 concerning ethyl acrylate; Opinion of 18 March 2021 concerning methyl acrylate; methyl propenoate; Opinion of 18 March 2021 concerning methyl methacrylate; methyl 2-methylprop-2-enoate; methyl 2-methylpropenoate; Opinion of 18 March 2021 concerning transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; Opinion of 18 March 2021 concerning allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester; Opinion of 18 March 2021 concerning mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride; Opinion of 10 June 2021 concerning triethylamine; Opinion of 10 June 2021 concerning di-n-butylamine; Opinion of 10 June 2021 concerning 4-nitrosomorpholine; Opinion of 10 June 2021 concerning difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether; Opinion 10 June 2021 concerning N,N-dimethyl-p-toluidine; Opinion of 10 June 2021 concerning potassium chlorate; Opinion of 10 June 2021 concerning sodium chlorate; Opinion of 10 June 2021 Concerning reaction mass of 1-(2,3-epoxypropoxy)-2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane; Opinion of 10 June 2021 concerning metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one; Opinion 16 September 2021 concerning lithium carbonate [1] lithium chloride [2] lithium hydroxide [3]; Opinion of 16 September 2021 concerning dimethyl propylphosphonate; Opinion of 16 September 2021 concerning dibutyltin maleate; Opinion of 16 September 2021 concerning dibutyltin oxide; Opinion of 16 September 2021 concerning clothianidin (ISO); (E)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine; Opinion of 16 September 2021 concerning cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with average molecular weight < 352 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof]; Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 352 g/mol ≤ average molecular weight < 704 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof];

Opinion of 16 September 2021 concerning nonylphenol, branched and linear, ethoxylated (with 704 g/mol ≤ average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof]; Opinion of 16 September 2021 concerning 1-phenylethan-1-one (1-phenylethylidene)hydrazone; Opinion of 16 September 2021 concerning 9-[2-(ethoxycarbonyl)phenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthylium chloride; Basic Red 1; Opinion of 16 September 2021 concerning picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide; Opinion of 16 September 2021 concerning diuron (ISO); 3-(3,4-dichlorophenyl)-1,1-dimethylurea; Opinion of 16 September 2021 concerning diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide; Opinion of 16 September 2021 concerning hydrogen sulphide, hydrogen sulfide; Opinion of 16 September 2021 concerning benzyl alcohol; Opinion of 16 September 2021 concerning resorcinol; 1,3-benzenediol; Opinion of 16 September 2021 concerning 2,2',6,6'-tetrabromo-4,4'-isopropylidenediphenol; tetrabromobisphenol-A; Opinion of 16 September 2021 concerning a reassessment at the request of the Commission to review the harmonised classification of lead (environment); Opinion of 26 November 2021 concerning 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol; Opinion of 26 November 2021 concerning 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol; Opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; Reaction mass of N-phenyl,N’-o-tolyl-phenylene diamine, N,N’-diphenyl-p-phenylene diamine and N,N’-di-o-tolyl-phenylene diamine; Opinion of 26 November 2021 concerning tetramethylene dimethacrylate; Opinion of 26 November 2021 concerning 7,7,9(or 7,9,9)-trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecane-1,16-diyl bismethacrylate; Opinion of 26 November 2021 concerning 2,2'-ethylenedioxydiethyl dimethacrylate; Opinion of 26 November 2021 concerning bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate; Opinion of 26 November 2021 concerning 4-methylimidazole; Opinion of 26 November 2021 concerning sulfur dioxide; Opinion of 26 November 2021 concerning 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one; Opinion of 26 November 2021 concerning benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate. (3) The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinion of 26 November 2021 concerning 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs. and in the RAC opinion of 16 September 2021 concerning dibutyltin oxide. The additional information has been assessed and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. It is therefore appropriate to introduce the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions.

(4) The RAC opinion of 16 September 2021 concerning the environmental toxicity of lead put forward various possible options to update the harmonised classification of lead for aquatic toxicity. These options give the possibility to either have a single entry for both lead in powder form (lead powder) and in massive form (lead massive) or to keep two separate entries, one for each form. However, as data for lead massive indicates a lower dissolution in water than for lead powder, a calculation in accordance with Part 4 of Annex I to Regulation (EC) No 1272/2008 leads to a less severe classification for lead massive. It is therefore appropriate to amend the existing aquatic toxicity classification for lead powder with regard to the M-factor and to introduce a different aquatic toxicity classification for lead massive. (5) In light of the RAC opinions, it is therefore appropriate to introduce or update the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments. (6) Regulation (EC) No 1272/2008 should therefore be amended accordingly. (7) As regards the classification of methyl methacrylate as a respiratory sensitiser and the classification of lithium carbonate, lithium chloride and lithium hydroxide as reproductive toxic substances the Commission has received additional information from stakeholders after obtaining the RAC opinions of 18 March 2021 and of 16 September 2021 respectively concerning those substances. Since that new scientific information requires further assessment by RAC, methyl methacrylate, lithium carbonate, lithium chloride and lithium hydroxide recommended in the RAC opinions should not be subject to harmonised classification and labelling at this stage. (8) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers, HAS ADOPTED THIS REGULATION:

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from 1 September 2025. However, suppliers may already before that date classify, label and package substances and mixtures in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation. This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 19 October 2023. For the Commission The President Ursula von der Leyen

Annex

ANNEX In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows: (1) the following entries are inserted following the order of the index numbers corresponding to each entry: Index NoChemical NameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M- factors and ATENotesHazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)015-204-00-5benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate479-100-5577705-90-9Repr. 1BH360F GHS08 Dgr H360F015-205-00-0benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1)278-305-575768-65-9Repr. 1BH360F GHS08 Dgr H360F015-206-00-6reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1)——Repr. 1BH360F GHS08 Dgr H360F015-207-00-1reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1)——Repr. 1BH360F GHS08 Dgr H360F 015-208-00-7dimethyl propylphosphonate242-555-318755-43-6 Muta. 1B Repr. 1B H340 H360Df GHS08 Dgr H340 H360Df 050-034-00-5dibutyltin maleate201-077-578-04-6 Muta. 2 Repr. 1B Acute Tox. 2 Acute Tox. 4 STOT RE 1 Skin Corr. 1 Eye Dam. 1 H341 H360FD H330 H302 H372 (immune system) H314 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H330 H302 H372 (immune system) H314 inhalation: ATE = 0,317 mg/L (dusts or mists) oral: ATE = 510 mg/kg bw 050-035-00-0dibutyltin oxide212-449-1818-08-6 Muta. 2 Repr. 1B Acute Tox. 3 STOT RE 1 Skin Irrit. 2 Eye Dam. 1 H341 H360FD H301 H372 (immune system) H315 H318 GHS08 GHS06 GHS05 Dgr H341 H360FD H301 H372 (immune system) H315 H318 oral: ATE = 170 mg/kg bw 603-244-00-1reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane—— Muta. 2 Repr. 1B H341 H360F GHS08 Dgr H341 H360F 603-245-00-72,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol221-665-53179-89-3Skin Sens. 1H317 GHS07 Wng H317603-246-00-23,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol211-477-1647-42-7 STOT RE 2 Aquatic Chronic 1 H373 (teeth, bones) H410 GHS08 GHS09 Wng H373 (teeth, bones) H410 M = 1604-099-00-74,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF216-036-71478-61-1Repr. 1BH360F GHS08 Dgr H360F604-100-00-0nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof]

500-315-8 500-024-6 500-045-0 500-209-1 248-762-5 243-816-4 248-291-5 — 230-770-5 248-743-1 247-555-7 248-293-6 — and others 127087-87-0 9016-45-9 26027-38-3 68412-54-4 27986-36-3 20427-84-3 27176-93-8 1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others Aquatic Acute 1 Aquatic Chronic 1 H400 H410 GHS09 Wng H410 M = 1 M = 10 606-155-00-6 cinnamaldehyde; 3-phenylprop-2-enal; cinnamic aldehyde; cinnamal; [1] (2E)-3-phenylprop-2-enal [2] 203-213-9 [1] - [2]104-55-2 [1] 14371-10-9 [2]Skin Sens. 1AH317 GHS07 Wng H317Skin Sens. 1; H317: C ≥ 0,01 %607-766-00-0tetramethylene dimethacrylate218-218-12082-81-7Skin Sens. 1BH317 GHS07 Wng H317607-767-00-67,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate276-957-572869-86-4Skin Sens. 1BH317 GHS07 Wng H317607-768-00-12,2'-ethylenedioxydiethyl dimethacrylate203-652-6109-16-0Skin Sens. 1BH317 GHS07 Wng H317607-769-00-7bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate255-894-742576-02-3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1500 mg/kg bw M = 1000 M = 1000 612-295-00-9benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine217-465-21861-40-1 Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H361d H315 H319 H317 H400 H410 GHS08 GHS07 GHS09 Wng H351 H361d H315 H319 H317 H410 M = 10 M = 10 612-296-00-4N,N-dimethyl-p-toluidine202-805-499-97-8 Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 H350 H332 H301 H373 (blood system, respiratory tract) H412 GHS08 GHS06 Dgr H350 H332 H301 H373 (blood system, respiratory tract) H412 inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 140 mg/kg bw 612-297-00-X1-phenylethan-1-one (1-phenylethylidene)hydrazone211-979-0729-43-1Skin Sens. 1H317 GHS07 Wng H317612-298-00-51,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.;273-227-868953-84-4 Repr. 1B Skin Sens. 1 H360FD H317 GHS08 GHS07 Dgr H360FD H317 613-346-00-84-nitrosomorpholine—59-89-2 Carc. 1B Muta. 2 STOT RE 1 H350 H341 H372 (liver) GHS08 Dgr H350 H341 H372 (liver) Carc. 1B; H350: C ≥ 0,001 %613-347-00-3difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether—119446-68-3 Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H319 H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H319 H410 oral: ATE = 1450 mg/kg bw M = 10 M = 10 613-348-00-99-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1213-584-9989-38-8 Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H301 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H301 H318 H317 H410 oral: ATE = 280 mg/kg bw M = 10 M = 1 613-349-00-44-methylimidazole212-497-3822-36-6 Carc. 1B Repr. 1B H350 H360Fd GHS08 Dgr H350 H360Fd 615-051-00-X3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate202-112-791-97-4

Carc. 2 Resp. Sens. 1 Skin Sens. 1A H351 H334 H317 GHS08 Dgr H351 H334 H317 Skin Sens. 1A; H317: C ≥ 0,001 %616-241-00-5foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea—173159-57-4 Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 H351 H400 H410 GHS08 GHS09 Wng H351 H410 M = 1000 M = 100 616-242-00-0picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide—137641-05-5 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H373 (blood system, thyroid) H400 H410 GHS08 GHS09 Wng H373 (blood system, thyroid) H410 M = 1000 M = 1000 (2) the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively: Index NoChemical NameEC NoCAS NoClassificationLabellingSpecific Conc. Limits, M-factors and ATENotesHazard Class and Category Code(s)Hazard statement Code(s)Pictogram, Signal Word Code(s)Hazard statement Code(s)Suppl. Hazard statement Code(s)006-015-00-9diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea206-354-4330-54-1 Carc. 1B STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H350 H373 (blood system) H400 H410 GHS08 GHS09 Dgr H350 H373 (blood system) H410 M = 100 M = 100 015-203-00-Xdiphenyl(2,4,6-trimethylbenzoyl)phosphine oxide278-355-875980-60-8 Repr. 1B Skin Sens. 1B H360Fd H317 GHS08 GHS07 Dgr H360Fd H317 016-001-00-4hydrogen sulphide, hydrogen sulfide231-977-37783-06-4 Flam. Gas 1A Press. Gas Acute Tox. 2 Aquatic Acute 1 H220 H330 H400 GHS02 GHS06 GHS09 Dgr H220 H330 H400 inhalation: ATE = 440 ppmV (gases)U016-011-00-9sulphur dioxide; sulfur dioxide231-195-27446-09-5 Press. Gas Acute Tox. 3 STOT SE 1 Skin. Corr. 1B H331 H370 (respiratory system) (inhalation) H314 GHS04 GHS06 GHS08 GHS05 Dgr H331 H370 (respiratory system) (inhalation) H314 inhalation: ATE = 1000 ppmV (gases)U, 5 017-004-00-3potassium chlorate223-289-73811-04-9 Ox. Sol. 1 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H301 oral: ATE = 100 mg/kg bw017-005-00-9sodium chlorate231-887-47775-09-9 Ox. Sol. 1 Acute Tox. 3 H271 H301 GHS03 GHS06 Dgr H271 H301 oral: ATE = 100 mg/kg bw082-013-00-1 lead powder; [particle diameter < 1 mm] 231-100-47439-92-1 Repr. 1A Lact. Aquatic Acute 1 Aquatic Chronic 1 H360FD H362 H400 H410 GHS08 GHS09 Dgr H360FD H362 H410 Repr. 1A; H360D: C ≥ 0,03 % M = 10 M = 100 082-014-00-7 lead massive: [particle diameter ≥ 1 mm] 231-100-47439-92-1 Repr. 1A Lact. Aquatic Chronic 1 H360FD H362 H410 GHS08 GHS09 Dgr H360FD H362 H410 M = 10603-057-00-5benzyl alcohol202-859-9100-51-6 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1B

H302 H319 H317 GHS07 Wng H302 H319 H317 oral: ATE = 1200 mg/kg bw 604-010-00-1resorcinol; 1,3-benzenediol203-585-2108-46-3 Acute Tox. 4 STOT SE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1B Aquatic Acute 1 H302 H370 (nervous system) H315 H319 H317 H400 GHS07 GHS08 GHS09 Dgr H302 H370 (nervous system) H315 H319 H317 H400 oral: ATE = 500 mg/kg bw M = 1 604-074-00-02,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A201-236-979-94-7 Carc. 1B Aquatic Acute 1 Aquatic Chronic 1 H350 H400 H410 GHS08 GHS09 Dgr H350 H410 606-034-00-8metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one244-209-721087-64-9 Acute Tox. 4 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 H302 H373 (blood system) H400 H410 GHS07 GHS08 GHS09 Wng H302 H373 (blood system) H410 oral: ATE = 320 mg/kg bw M = 10 M = 10 607-032-00-Xethyl acrylate205-438-8140-88-5 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H331 H312 H302 H335 H315 H319 H317 GHS02 GHS06 Dgr H225 H331 H312 H302 H335 H315 H319 H317 inhalation: ATE = 9 mg/L (vapours) dermal: ATE = 1800 mg/kg bw oral: ATE = 1120 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Irrit. 2; H315: C ≥ 5 % Eye Irrit. 2; H319: C ≥ 5 % D607-034-00-0 methyl acrylate; methyl propenoate 202-500-696-33-3 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 H225 H331 H312 H302 H335 H315 H319 H317 GHS02 GHS06 Dgr H225 H331 H312 H302 H335 H315 H319 H317 inhalation: ATE = 3 mg/L (vapours) dermal: ATE = 1100 mg/kg bw oral: ATE = 500 mg/kg bw D 607-223-00-8transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate405-060-5118712-89-3 Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H351 H302 H370 (nervous system) H400 H410 GHS08 GHS07 GHS09 Wng H351 H302 H370 (nervous system) H410 EUH066 oral: ATE = 580 mg/kg bw M = 1000 M = 1000 607-246-00-3 allyl methacrylate; 2-methyl-2-propenoic acid 2-propenyl ester 202-473-096-05-9 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 H226 H330 H311 H302 H400 GHS02 GHS06 GHS09 Dgr H226 H330 H311 H302 H400 inhalation: ATE = 1,5 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 400 mg/kg bw 612-004-00-5triethylamine204-469-4121-44-8 Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 H225 H331 H311 H301 H314 H318 GHS02 GHS06 GHS05 Dgr H225 H331 H311 H301 H314 inhalation: ATE = 7,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 % 612-049-00-0di-n-butylamine203-921-8111-92-2 Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 H226 H330 H311 H301 H314 H318 GHS02 GHS06 GHS05 Dgr H226 H330 H311 H301 H314 EUH 071 inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw oral: ATE = 220 mg/kg bw 612-056-00-9 N,N-dimethyl-m-toluidine; [1] N,N-dimethyl-o-toluidine [2]

204-495-6 [1] 210-199-8 [2]121-72-2 [1] 609-72-3 [2]Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 H331 H311 H301 H373 H412 GHS06 GHS08 Dgr H331 H311 H301 H373 H412 C613-088-00-61,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one220-120-92634-33-5 Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 H330 H302 H315 H318 H317 H400 H410 GHS06 GHS05 GHS09 Dgr H330 H302 H315 H318 H317 H410 inhalation: ATE = 0,21 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1 613-127-00-7mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride246-147-624307-26-4 Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 H332 H301 H412 GHS06 Dgr H332 H301 H412 inhalation: ATE = 2,8 mg/L (dusts or mists) oral: ATE = 270 mg/kg bw 613-307-00-5clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine433-460-1210880-92-5 Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 H361f H302 H370 (nervous system) H400 H410 GHS08 GHS07 GHS09 Dgr H361f H302 H370 (nervous system) H410 oral: ATE = 390 mg/kg bw M = 10 M = 100 616-035-00-5 cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1] (2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2] 261-043-0 [1]

• [2] 57966-95-7 [1] 166900-80-7 [2] Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 H361fd H302 H373 (blood system, thymus, eyes) H317 H400 H410 GHS08 GHS07 GHS09 Wng H361fd H302 H373 (blood system, thymus, eyes) H317 H410 oral: ATE = 360 mg/kg bw M = 1 M = 1 616-104-00-Xbenalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate275-728-771626-11-4 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 H302 H400 H410 GHS07 GHS09 Wng H302 H410 oral: ATE = 1000 mg/kg bw M = 1 M = 1